Analysis of α-synuclein seed amplification assay in carriers of GBA1 and LRRK2 pathogenic variants.

BackgroundThe α-synuclein seed amplification assay (αS-SAA) represents a promising strategy for identifying individuals with α-synuclein pathology, empowering development of tailored Parkinson's disease (PD) therapeutics and clinical trial design.ObjectiveTo assess the αS-SAA in cerebrospinal fluid (CSF) from PD patients, non-manifesting carriers (NMCs) and non-manifesting non-carriers (NMNCs) of pathogenic Detecting the pathology at the basis of Parkinson's disease among different genetic groups.